FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Nat Rev Cancer. 2008 Dec;8(12):942-56. doi: 10.1038/nrc2524.

Abstract

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Glycosylphosphatidylinositols / physiology
  • Humans
  • Macular Degeneration / drug therapy
  • Membrane Proteins / physiology
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic / prevention & control
  • Placenta Growth Factor
  • Pregnancy Proteins / physiology
  • Receptors, Vascular Endothelial Growth Factor / physiology
  • Vascular Endothelial Growth Factor A / physiology
  • Vascular Endothelial Growth Factor B / physiology*
  • Vascular Endothelial Growth Factor Receptor-1 / physiology*
  • Vascular Endothelial Growth Factor Receptor-2 / physiology

Substances

  • Angiogenesis Inhibitors
  • Glycosylphosphatidylinositols
  • Membrane Proteins
  • PGF protein, human
  • PIGF protein, human
  • Pregnancy Proteins
  • VEGFA protein, human
  • VEGFB protein, human
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor B
  • Placenta Growth Factor
  • FLT1 protein, human
  • Receptors, Vascular Endothelial Growth Factor
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2